These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss. Trouillot TE; Pace DG; McKinley C; Cockey L; Zhi J; Häeussler J; Guerciolini R; Showalter R; Everson GT Am J Gastroenterol; 2001 Jun; 96(6):1888-94. PubMed ID: 11421247 [TBL] [Abstract][Full Text] [Related]
3. Effect of orlistat on cardiovascular disease risk in obese adults. Swinburn BA; Carey D; Hills AP; Hooper M; Marks S; Proietto J; Strauss BJ; Sullivan D; Welborn TA; Caterson ID Diabetes Obes Metab; 2005 May; 7(3):254-62. PubMed ID: 15811142 [TBL] [Abstract][Full Text] [Related]
4. The effect of orlistat on the fatty acid composition of serum lipid fractions in obese subjects. Vidgren HM; Agren JJ; Valve RS; Karhunen LJ; Rissanen AM; Uusitupa MI Clin Pharmacol Ther; 1999 Sep; 66(3):315-22. PubMed ID: 10511068 [TBL] [Abstract][Full Text] [Related]
5. The long-term influence of orlistat on dietary intake in obese subjects with components of metabolic syndrome. Svendsen M; Helgeland M; Tonstad S J Hum Nutr Diet; 2009 Feb; 22(1):55-63. PubMed ID: 19192027 [TBL] [Abstract][Full Text] [Related]
6. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Rössner S; Sjöström L; Noack R; Meinders AE; Noseda G Obes Res; 2000 Jan; 8(1):49-61. PubMed ID: 10678259 [TBL] [Abstract][Full Text] [Related]
7. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia. Micić D; Ivković-Lazar T; Dragojević R; Jorga J; Stokić E; Hajduković Z Med Pregl; 1999; 52(9-10):323-33. PubMed ID: 10624380 [TBL] [Abstract][Full Text] [Related]
8. Orlistat increases serum paraoxonase activity in obese patients. Audikovszky M; Pados G; Seres I; Harangi M; Fülöp P; Katona E; Illyés L; Winkler G; Katona EM; Paragh G Nutr Metab Cardiovasc Dis; 2007 May; 17(4):268-73. PubMed ID: 17134960 [TBL] [Abstract][Full Text] [Related]
9. A double-blind randomized placebo-controlled trial of orlistat for the treatment of nonalcoholic fatty liver disease. Zelber-Sagi S; Kessler A; Brazowsky E; Webb M; Lurie Y; Santo M; Leshno M; Blendis L; Halpern Z; Oren R Clin Gastroenterol Hepatol; 2006 May; 4(5):639-44. PubMed ID: 16630771 [TBL] [Abstract][Full Text] [Related]
10. The anti-obesity agent Orlistat is associated to increase in colonic preneoplastic markers in rats treated with a chemical carcinogen. Garcia SB; Barros LT; Turatti A; Martinello F; Modiano P; Ribeiro-Silva A; Vespúcio MV; Uyemura SA Cancer Lett; 2006 Aug; 240(2):221-4. PubMed ID: 16377080 [TBL] [Abstract][Full Text] [Related]
11. Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial. Harrison SA; Fecht W; Brunt EM; Neuschwander-Tetri BA Hepatology; 2009 Jan; 49(1):80-6. PubMed ID: 19053049 [TBL] [Abstract][Full Text] [Related]
12. Orlistat. Wong NN; Cheng-Lai A Heart Dis; 2000; 2(2):174-81. PubMed ID: 11728255 [TBL] [Abstract][Full Text] [Related]
13. Body fat loss achieved by stimulation of thermogenesis by a combination of bioactive food ingredients: a placebo-controlled, double-blind 8-week intervention in obese subjects. Belza A; Frandsen E; Kondrup J Int J Obes (Lond); 2007 Jan; 31(1):121-30. PubMed ID: 16652130 [TBL] [Abstract][Full Text] [Related]
14. The antiproliferative effect of dietary calcium on colonic epithelium is mediated by luminal surfactants and dependent on the type of dietary fat. Cancer Res; ; . PubMed ID: 8428359 [TBL] [Abstract][Full Text] [Related]